Study of WSD0922-FU for advanced EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called WSD0922-FU for people with advanced non-small cell lung cancer that has a specific EGFR gene change. It aims to see if the drug can help when previous EGFR treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or spread non-small cell lung cancer with an EGFR mutation.
- You have tried at least one previous EGFR treatment, and your disease has gotten worse.
- You are well enough to be up and about (ECOG 0 or 1).
- You agree to use birth control if there is any chance of pregnancy.
- You do not have active brain metastases or other major health issues like severe heart disease or lung scarring.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
This trial tests a new combination treatment (WSD0922-FU plus osimertinib) for people with advanced non-small cell lung cancer (NSCLC) that has a specific EGFR mutation. The goal is to see if the combination is safe and effective.
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new EGFR Mutation Positive Advanced Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.